Brought to you by 
Ipsen gets rights to PhotoCure's Hexvix for bladder cancer; rights returned
11 Jun 2020
Executive Summary
Ipsen has licensed global marketing rights (excluding the US and Nordic countries) to PhotoCure ASA’s (cancer and dermatology therapeutics) Hexvix (hexaminolevulinate) for the diagnosis and resection of bladder cancer.
Deal Industry
- Medical Devices
-
Pharmaceuticals
- Radiopharmaceuticals, Contrast Agents
-
Medical Devices
- Diagnostic Imaging Equipment & Supplies
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ipsen gets rights to PhotoCure's Hexvix for bladder cancer; rights returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice